Patients with advanced hepatocellular carcinoma treated with nivolumab plus ipilimumab had an improvement in overall survival compared with standard-of-care TKIs.
Treatment with regorafenib in patients with unresectable hepatocellular carcinoma and poor liver function may lead to serious side effects that may result in discontinuation of the treatment.
Patients with advanced hepatocellular carcinoma treated with frontline pembrolizumab plus lenvatinib showed a 3-year or more response among 35% of responders, although additional efficacy results from the trial are consistent with previous findings from the phase 3 LEAP-002 trial.
Three patients with resectable hepatocellular carcinoma experienced significant tumor necrosis greater than 70% after neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc, in addition to adjuvant cemiplimab.